Introduction of our Stem Cell Treatment and doctors

Tiantan Puhua hospital uses the newest breakthroughs to provide effective and safe stem

cell treatments to a wide range of neurological and physical disorders. We use the latest

knowledge of stem cells behavior in the human body within an individually tailored medical

plan according to the patient’s condition. Using stem cell transplantation, intensive

physiotherapy and medicines, this combination of therapies has so far proved itself to be

most efficient in bringing a high level of recovery to our patients.

What are stem cells?

What are stem cells?

Stem cells are the master cells of the human body. What

define stem cells from other cells is their ability to

self-generate themselves and the ability to differentiate

into other cell types. Stem cells are at the center of a

new field of science called regenerative medicine. All

stem cells, regardless of their source, have three general

properties: they are capable of dividing and renewing

themselves for long periods; they are unspecialized; and

they can give rise to specialized cell types. Self-regeneration is the ability of stem cells to

divide and produce more stem cells. During early development, the cell division is

symmetrical i.e. each cell divides to gives rise to daughter cells each with the same

potential. Later in development, the cell divides asymmetrically with one of the daughter

cells produced, also a stem cell and the other a more differentiated cell (such as brain cell,

blood cell, etc.). When stem cells are being transplanted into the body and arrive (through

migration or through direct injection) into injured part of the brain being targeted for tissue

regeneration, the stem cells are come into contact with microenvironment in the body,

where the stem cells can settle into the tissue surrounding them.

Stem cells can typically be broken into four types:

Embryonic stem cells - Stem cells taken from

human embryos

Fetal stem cells- Stem cells taken from aborted

fetal tissue

Umbilical stem cells - Stem cells take from

umbilical cords

Adult stem cells - Stem cells taken from adult

tissue

At Tiantan Puhua hospital 7 main types of stem cells are being used:

1. Human fetal Neural Stem Cells (hNSC);

2. Human bone Marrow-derived mesenchymal Stem cells (hBM-MSC);

3. Human umbilical cord-derived mesenchymal stem cells (hUCMSC);

4. Human retinal pigment epithelial cells (hRPE):

5. Human insulin producing cells (hIPC, unipotent), clinical application: Diabetes.

6. Human adipose-derived mesenchymal stem cells (hAMSC), clinical application:

cosmetic treatment, and an alternative treatment of BMMSC.

7. Human hematopoietic stem cells (hHSC), clinical application: reestablish

hematopoietic system.

Human fetal Neural Stem cells (hNSC) are

self-regenerating, multipotent cells, found in the human brain

which have the potential to differentiate into three major cell

types: nerve cells (neurons), astrocytes and oligodendrocytes, and

to self renew sufficiently to provide an adequate number of cells

in the brain. When brain cells are damaged or are dying, due to a

disease or an injury, fetal neural stem cells are the best known

source for treatment. Since most brain injuries, stroke,

degenerative diseases and Demyelinating disorders affect several

areas in the brain, the most effective and safe procedure to

deliver neural stem cell into the brain is via a Lumbar Puncture

(also called Spinal Tap): a spinal injection in the lumbar area

(lower back) into the CSF (Cerebral Spinal Fluid). In our clinic, hNSC is applied to treat the

patients with Cerebral Palsy, Brain Injury, Stroke, Amyotrophic Lateral Sclerosis (ALS), Batten

Diesease, Degenerative Diseases, and other neurological disorders.

Human Bone marrow mesenchymal stem cells () are self-renewing

and multipotent stem cells existing in bone marrow tissue, which in

vitro are able to differentiate into certain cell types of all three

germ layers, such as neuron, cartilage, osteoblast, hepatocyte and

lipocyte cells . These cells regulate immune activity and provide

niche (microenvironment) for surrounding cells. hBM-MSC can be

extracted from adult bone marrow or from fetal bone marrow.

Clinically, these cells have been identified significantly improve the

conditions of the patients, who suffer from autoimmune diseases,

nervous system diseases, coronary disease, hematoloic malignancy,

or graft versus host disease(GVHD).

Human umbilical cord-derived mesenchymal stem cells (h) are

directly isolated from umbilical cord tissue of infants. hUCMSC

are very similar to the mesenchymal cells derived from bone

marrow tissue, because they also can be induced and derived

into distinct cell types. These cells are used clinically as an

alternative treatment as hBM-MSC.

Human retinal pigment epithelial cells (hRPE) are of neuroectodermal origin and are found

in the inner layer of the retina. These cells produce levodopa.

They can be isolated from fetal and adult human eyes, grown

easily in culture, and stored frozen for prolonged periods.

Preclinical studies suggest the safety and effectiveness of human

RPE cells as a suitable cell type to serve as a potential durable

source of levodopa producing donor for implantation into the

striatum of patients.

In recent years, hRPE cell transplantation has been used to treat

Parkinson's disease. RPE cells are easily obtained from donated

eyes and can be proliferated in vitro. Then the cells are attached

to microcarriers and transplanted into patients' striatum. The

stereotaxic intrastriatal implantation produced a constant amelioration of patients'

parkinsoniams without using any immune suppression.

hRPE cells were obtained from donated eyes, which are usually stored in an eye bank. The

cells can be easily prepared and they proliferate abundantly in vitro. It is generally

calculated that one eye can be used to treat several patients. Compared with cells isolated

from FVM tissue, fetal RPE is obtained from aborted fetus. Since there are ethical

controversy concerns of using embryos in transplantation, it will be of great advantage to

obtain and use RPE cells for cell replacement therapy.

Human insulin producing cells (hIPC, unipotent), clinical

application: Diabetes.

Human adipose-derived mesenchymal stem cells (hAMSC),

clinical application: cosmetic treatment, and an alternative

treatment of BMMSC.

Human hematopoietic stem cells (hHSC), clinical application:

reestablish hematopoietic system.

Stem Cell laboratory SOP

The stem cells we produce at TP undergo several tests for quality control, which includes

and provides:

1. Safety control of original material:

We test for the following infectious diseases of the donor, including HIV, HAV, HBV, HCV, Syphilis etc.

All the results should be negative.

2. Filtration of the cultured cell:

We filter cells by checking the surface antigen and immunogenicity through inducing cell

differentiation and testing FACS regularly.

3. Double checking of Safety before clinical use

4. Before we deliver the stem cells to patients, we do a series of test to avoid virus infection,

bacillus, tumors growth, mycoplasma, mutation, residual culture medium, etc. These tests will

insure the safety of the stem cells.

Tiantan Puhua hospital can treat patients with the following diseases. If you don’t see

your disease or injury listed below, please contact us for an evaluation.

� Stem Cell Treatment for neurological disease, including:

1. CP (Cerebral Palsy )

2. PD (Parkinson’s disease )

3. Batten (Batten’s disease)

4. MSA (all types of Multiple System Atrophy)

5. MS (Multiple Sclerosis)

6. Down’s syndrome

7. NMO (neuromylitis optica)

8. HD (Huntingtons disease)

9. ALS (Amyotrophic Lateral Sclerosis)

10. BI (Brain Injury)

11. Dementia

12. MG (Myathenia Gravis)

13. Muscular Dystrophy

14. PLS (Primary Lateral Sclerosis)

15. PSP (Progressive Supranuclear Palsy)

16. Spinal Cord Injury

17. Stroke

18. PMS

19. Ataxia

20. Post Meningitis Syndrome

� Stem cell treatment for DM (diabetes mellitus)—type 1 and type 2

� Cancer

� Glioma

� Liver Cirrhosis

� Brain surgery

TP Biomedical Stem Cell Research Centre

As a worldwide leading hospital in stem cell therapy, Tiantan Puhua Hospital owns a

research center that performs research and development (R and D) of stem cells and related

products, which are applied to serve our patients. Our high quality stem cells are all

produced from our own Stem Cell Research Centre laboratories. In Puhua hospital stem cell

research center, we have a strong and well trained professional team including doctors,

scientists, technicians and quality control experts. Therefore, we can provide the highest

quality and safest stem cells for our patients.

Introduction of the Senior Scientists of Stem cell Research Centre

Dr. Mingyuan Zhou, Ph.D

Principle investigator, Director of R&D

Stem Cell Research Institute of Beijing Tiantan Puhua Hospital

Research Interests and expertise:

Stem cell biology, stem cell therapy and gene therapy

Resume:

Associate Director: School of Medicine, Vector Core, Gene Therapy Center, University of

Pennsylvania, Philadelphia, PA, USA

Senior Scientist: Wistar institute, Tumor Biology, Philadelphia, PA, USA

Assistant Professor: School of Medicine, Northwestern University, Chicago, IL,

USA

Senior Research Associate: School of Medicine, Chicago University, Chicago, IL, USA

Publication

• Ablation of epithelium early epithelial differentiation-associated (EEDA) protein in

mice down regulates the skin and corneal epithelium differentiation and wound

healing. In preparation

• Transcriptional profiling of stem cells versus transient amplifying cells: a comparison

of limbal and corneal epithelial basal cells.J biol.chem.281(28):19600-19609, 2006.

• A hierarchy of proliferative cells exists in mouse lens epithelium: implications on lens

maintenance. Investigative Ophthalmology and Visual Science, 47(7):2997-3003,

2006.

• ABCG2-dependent side population cells exhibiting stem cell features in the human

and rabbit ocular surface epithelia. J. Cell Science, 118(8):1715-1724, 2005.

Dr. Song Rong, MD.

Senior Scientist

Cell Center, Beijing Tiantan Puhua International

Hospital, Beijing, P.R.China

Research Interests and expertise:

• Stem cell therapy on kidney diseases

• Mechanism of glomerulonephritis

Resume:

• Post Doctor (2007-2009): Division of Nephrology, Rheinisch-Westfaelische

Technische

• Hochschule University of Aachen, Aachen, Germany

• Post Doctor (2005-2007): Renal Division, Peking University First Hospital, Beijing,

P.R.China

• M.D. (2002-2005): Division of Nephrology, Rheinisch-Westfaelische Technische

• Hochschule University of Aachen, Aachen, Germany

Publication:

• Mesenchymal stem cells prevent progressive experimental renal failure but

maldifferentiate into glomerular adipocytes. J Am Soc

Nephrol. 2007 Jun;18(6):1754-64.

• Transplanted mesenchymal stem cells accelerate glomerular

healing in experimental glomerulonephritis. J Am Soc Nephrol.

2006 Aug;17(8):2202-12.

• Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in

experimental glomerulonephritis.J Am Soc Nephrol. 2006 Apr;17(4):1054-62.

• Complement C5 mediates experimental tubulointerstitial

fibrosis. J Am Soc Nephrol. 2007 May;18(5):1508-15.

• PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am

Soc Nephrol. 2008 Feb;19(2):281-9.

• Urinary podocyte loss is a more specific marker of ongoing glomerular damage than

proteinuria. J Am Soc Nephrol. 2005 Jun;16(6):1733-41.

• R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without

aggravating podocyte injury. ASN 2009， TH-PO561

• Macrophage Migration Inhibitory Factor (MIF) Deficiency Attenuates Renal Damage

in Experimental Nephrotoxic Nephritis

• Transplantation of PDGF-C Knockout Bone Marrow to Wild Type Mice Attenuates

Renal Fibrosis in UUO mice. manuscript in preparation.2009

• MSC Conditioned Medium Alleviates Renal Damage in Experimental Mesangial

Proliferative Rat’s Model. manuscript in preparation. 2009

Dr. Ying Zhang, PhD., M.D.

Director

Cell Center, Beijing Tiantan Puhua International

Hospital, Beijing, P.R.China

Research Interests and expertise:

• Clinical trial on stem cell therapy for Diabetes

• Oriented differentiation of stem cells and clinical application, including pancreatic

islet-derived progenitor cells, embryonic stem cells and iPS

Resume:

• Scientist: Cell therapy Center of Beijing Xuanwu Hospital, Beijing, P.R.China

• Ph.D., M.D. Capital Medical University, Beijing, P.R.China; Tianjin Medical

University, Tianjin, P.R.China

Publications:

• Insulin-producing cells from human pancreatic islet-derived progenitor cells

following transplantation in mice. J. Cell Biol. 2010

• Isolation and in vitro characterization of pancreatic progenitor cells from the islets of

diabetic monkey models. Int. J. Biochem. Cell Biol. 2006

• Improving infection efficiency of adult cynomolgus monkey mesenchymal stem cells

with lentiviral vectors. Chin J Biotech. 2010, June 25; 26(6): 789−795

• Proliferation and differentiation potential of hIPCs derived from fetus and adult. Chin

J Cell Biol. 2010,Aug ;32(4):562-568

• Assessment of the differentiation potential of human adult pancreatic islet-derived

stem cells. ATC 9

Dr. Yuan Chen

Scientist, Cell Center, Beijing Tiantan Puhua International Hospital, Beijing, P.R.China

Research Interests and expertise:

• Immunocharacteristics of MSCs

• Establish animal models for the treatment of human disease

• The safety of the stem cells` clinical application

Resume:

• Master of Medicine: Peking Union Medical College, Tsinghua University, Beijing,

P.R.China

Publications

• Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2

dependent regulatory dendritic cell population.J Blood, 2009,113,46-57.

• Sca1+ Mesenchymal Stem Cells Induce Hemopoietic Stem Cells to Differentiate Into

Dendritic Cells. J Basic & Clinical Medicine,2009,3,11-13

• The biological characteristics of Primitive pluripotent stem cells in mouse. Exp.

hematology.11, 2008.

• The effect of Flk-1+MSC to the function of DC. Exp.hematology,11.2008

Clinical Specialist:

Dr. Xiaodi Han, MD, PhD

Director, Neurosurgery department, Beijing Tiantan Puhua International

Hospital

Research Interests and expertise:

• Neural Stem cell in the treatment of neurodegeneration disease and trauma

patients.

• Tumor vaccine in treatment of malignant glioma patients

• Clinical Management of Brain tumor and Cerebral Aneurysm (see publication)

• The application of neuronavigation system during operation (intraoperative

ultrasound application)

Resume:

• Research Associate, Department of Neurosurgery, University of Rochester Medical

Center, Rochester, New York, USA

• Visit scholar, Wichita State University and Bio-Communication Research institute,

Wichita, Kansas, USA

• Research Fellow: Department of Neurosurgery, The Alfred Hospital, Melbourne,

Australia

• Neurosurgeon and Researcher: Department of Neurosurgery, Beijing Tiantan

Hospital & Beijing Neurosurgical Institute, Beijing, China

•

Publications:

Book:

• Hand Book of Neurosurgery (Chinese version) (co-translator): Shandong Science &

Technology Press, 2004

Papers published and Presentations:

• Inhibition of intracranial glioma growth by endometrial regenerative cells, Cell Cycle

8:4,1-5;2009

• Imipramine Treatment contributes to recovery of congnitive but not motor function

following controlled cortical impact injury in mice, Journal of Neurotrauma

(accept),2010

• Cerebral aneurysm associated with von-Recklinghausen’s neurofibromatosis: A case

report. Surg Neurol 1998: 50; 592-596

• Efficacy and toxicity evaluation of fotemustine administered intravenously after

surgical resection in adult patients with supratentorial malignant glioma.

International Journal of Medicine (Chinese)，1999，3(12); 16-19

• Cauda equina tumors: Chin J Neurosurg 1998: 14(6), 328-330

• Intra-artery infusion of RMP-7 may increase the permeability of BTB。China Medical

Tribune，Dec, 1997.

• The markers which can evaluate the prognosis of astrocytic gliomas.China Medical

Tribune, May,1997.

• A special type of meningioma。China Medical Tribune，Oct. 1997.

• Primary pulmonary menigiomas. China Medical Tribune，March, 1998.

• Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid

(review). Foreign Medical Sciences Section on Neurology and Neurosurgery, 2001:

28(2), 128-131

• Combination of Intraoperative Embolization with Surgical Resection for Treatment of

Giant Cerebral AVMs. J. Neurosurg.2001, 94: 158A-159A.

• Neuronavigation on Low-grade Glioma Surgery. (presentation on the 2nd Chinese

Congress on Minimally Invasive Neurosurgery. Held in Shanghai, March 28-30, 2001).

• The expression of thrombospondine1 (TSP1) and thrombospondine2 (TSP2) mRNA

and their correlated with microvessels density in gliomas.(In: Proceedings of the

World Federation of Neurosurgical Societies 12th World Congress of Neurosurgery.

Sydney September 2001)

• Intraoperative real-time ultrasound combine with MRI navigation system in

resection of deep-seated brain lesions. (2003 Xi’an International Neurosurgery

Symposium,China)

• The supraorbital keyhole approach with eyebrow incisions for treating lesionsin the

anterior fossa and sellar region. CHINESE MEDICAL JOURNAL (Eng). 2004,117 (3)

323-326

• Clinical features and minimally invasive surgery of insular lesions: report of 42 case

CHINESE MEDICAL JOURNAL (Eng). 2004, 117(7), 1104-1108

• Efficacy evaluation of fotemustine administered in adult patients with supratentorial

malignant glioma CHINESE PHARMACEUTICAL JOURNAL (Chinese) 2004, 39 (10),

788-790

• Different expression of VEGF receptor KDR and FLT-1 mRNA and its correlation with

pathology of gliomas BEIJING MEDICAL JOURNAL (Chinese) 2004, 26 (1) 10-13

• De novo proliferation following diffuse traumatic axonal injury in rats ( poster in 7th

International Neurotrauma Symposium 2004, Adelaide)

•

Dr. Jingli Zhou, MD

Director, Neurology department, Beijing Tiantan Puhua International

Hospital

Research Interests and expertise:

• Neural stem cell treatment for neurological diseases;

• Diagnosis and treatment for degeneration neural diseases.

Resume:

• Duke University - Research on Spirituality and Health

• Harvard university - Mind/body Medicine-positive psychology

• Michigan State University - Visiting scholar in neuropsychology;

• Beijing Medical University - Research methods of neuropsychology

• Senior Physician / Associate Chief Physician and Associate Professor of Neurology,

Harbin Medical University No. 2 Hospital, Harbin, China

Publications:

• "Brain Function" (Chapter Author: Zhou Jingli) in Neurology, Editor: Wang Weizhi,

People's Medical Publishing house, 2006(1).

• "Aphasia" (Chapter Author: Zhou Jingli) in Neurology, 4th Edition, Editors: Wang

Weizhi, Luo Zhuming, People's Medical Publishing House, 2001.

• Language Disorder in Patients with Perventricular Infarction. Chinese Journal of

Clinical Psychology, 2001 (4):291-292. Authors: Zhou Jingli, Kong Fanhui, and Wang

Weizhi.

• Global Aphasia in Patients Without Lesions in Frontal Cortex on CT. Journal of

Harbin Medical University, 1999(1):65-66. Authors: Zhou Jingli, Kong Fanhui, Zhang

Liling et al.

• "Language Disorder," (Chapter Author: Zhou Jingli) in Advantage for Attending,

Editors: Wang Weizhi, Hu Weiming, Peking Union Medical College Press, 1998.

• Treatment of Epilepsy with Vigabartrin. Chinese Journal of Neurology,

1996(6):371-372. Authors: Zhou Jingli, Wang Weizhi.

• Strokes Which May be Easily Neglected. Chinese Journal of Practical Internal

Medicine, 1995 (5): 293-294. Authors: Zhou Jingli, Wang Weizhi.

Dr. Qiong Zhang, MD.

Director, Diabetes treatment center, Beijing Tiantan Puhua

International Hospital

Research Interests and expertise:

• Stem cell treatment for Type-1 Diabetes and Type-2 Diabetes

Resume:

• MD. Beijing University of Traditional Chinese Medicine

Publications:

• Having participated a Great Item Supported by The Nature Science Foundation of

Henan Province Science Committee:" Clinical and Experimental Research on

Dihuang Guanshitong Granule in Preventing Recurrence of Esophageal Cancer after

Radiotherapy."

• Having won the second award of Provincial Achievements "Effects of Tonifying Qi,

Nourishing Yin and Promoting the Blood Circulation Method on Non-enzyme

Glycosylation in Rat Renal Tissue."

• Study on m ental stress life events in patients with cyclom astopathy of liver

stagnation syndrome type, Chinese Journal of Integrated Traditional and Western

Medicine, 2007,27(6):509-512. Zhang Qiong , et al.

• Hyperplasia of mammary gland differentiation typing study, China Journal of

Traditional Chinese Medicine and Pharmacy, 2006,21(5):316-317. Zhang Qiong , et

al.

• Study of mammary glands of psychological stress, Liaoning Journal of Traditional

Chinese Medicine, 2005, 32(10): 1013-1014. Zhang Qiong, et al .

• Observation of TCM-WM therapy of gastric cancer and surrounding lymph node

metastases after treatment, Chinese Journal of Integrated Traditional and Western

Medicine, 1998,18(9):567. Zhang Qiong.

• Therapeutic efficacy comparison between baihuasheshecao injection associated

with ep scheme and simple ep scheme in treating non-small-cell carcinoma of the

lung, Journal of Henan Medical College for Staff and Workers, 2001,13(1): 40,45. Z

hang Qiong , et al .

• Clinical observation on treating 5 cases of primary liver cancer by a combination of

chinese herbs and tamoxifen with adding TAE, Henan Journal of Oncology,

2002,15(2): 130-131. Zheng yu ling, Zhang qiong .